An initial FDA approval was granted for a generic version of Dapagliflozin on April 6, 2026. This approval, designated ANDA 211535, signifies the availability of a new generic option for the drug.
What this means
The initial FDA approval of a generic version of Dapagliflozin represents a key milestone in drug accessibility. Generic drug approvals are crucial for fostering competition in the pharmaceutical market, which often translates into more affordable treatment options for patients. An Abbreviated New Drug Application (ANDA) approval indicates that the generic drug is bioequivalent to its reference listed drug (RLD), meaning it performs in the same way as the original drug in the body. It also means the generic drug has the same active ingredient, strength, dosage form, and route of administration as the RLD, and meets the same strict quality and manufacturing standards. This ensures that patients receive a therapeutically equivalent product. The sponsor, CIPLA, can now proceed with manufacturing and marketing this generic version, subject to any remaining patent or exclusivity protections on the RLD. This development expands the availability of Dapagliflozin, a medication widely used for various conditions, by introducing a cost-effective alternative.
Source
The information regarding this initial approval was obtained from the U.S. Food and Drug Administration (FDA) website, specifically the Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) database. The approval for ANDA 211535 was recorded on April 6, 2026, on accessdata.fda.gov.